KULMEET KUNDLAS: Open Payments
NPI 1336293497 · SEBRING, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$618 in 31 payments from 11 companies in 2025. Trend: 2023 $421 · 2024 $419 · 2025 $618
Food & beverage: $618
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $92 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $89 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| PFIZER INC. | 2 | $52 |
| Dexcom, Inc. | 2 | $49 |
| Abbott Laboratories | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Lilly USA, LLC | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
Products named: JARDIANCE, CAPLYTA, Ozempic, FARXIGA, ELIQUIS, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, TRELEGY ELLIPTA.
Industry payments across FL — which companies pay providers there.
